The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

decimmune.com

Total Raised

$10.54M

Deal Terms

2

Decimmune Therapeutics Funding, Decimmune Therapeutics Valuation & Decimmune Therapeutics Revenue

5 Fundings

Decimmune Therapeutics's latest funding round was a Grant - II for $3M on October 3, 2014.

Decimmune Therapeutics's valuation in October 2006 was $7.25M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

10/3/2014

Grant - II

$3M

0

FY undefined

1

2/26/2013

Series B - II

$99M

0

FY undefined

10

9/28/2010

Series B

$99M

0

FY undefined

10

9/28/2010

Grant

$99M

0

FY undefined

0

10/13/2006

Series A

$99M

$7.25M

0

FY undefined

0

Date

10/3/2014

2/26/2013

9/28/2010

9/28/2010

10/13/2006

Round

Grant - II

Series B - II

Series B

Grant

Series A

Amount

$3M

$99M

$99M

$99M

$99M

Investors

Valuation

$7.25M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

10

10

0

0

Decimmune Therapeutics Deal Terms

2 Deal Terms

Decimmune Therapeutics's deal structure is available for 2 funding rounds, including their Series B from September 28, 2010.

Round

Series B

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

You May Also Like

S
Stem Cells Bank

Stem Cells Bank Biotechnological Company engaged in development of autovaccines for treating oncological diseases and tuberculosis, produced on the basis of autologous dendritic cells (cells extracted from the organism of the very patient to be given the vaccine). In the framework of thus project it is planned to develop and launch a vaccine for treating oncological diseases and tuberculosis, produced on the basis of cells extracted from the organism of the very patient to be given the vaccine.

D
Dare Bioscience

Dare Bioscience is a healthcare company committed to the development and commercialization of innovative products in women's reproductive health. We believe there is an unmet need globally for new product candidates that expand options, improve outcomes and are easy to use. By advancing these products, we seek to expand choices and to make a difference in the lives of women worldwide.

L
LeukoSight

LeukoSight Inc. is an early stage biotechnology company developing a line of therapeutics that can be used to treat autoimmune and inflammatory diseases.

moksha8 Logo
moksha8

Moksha8 is a specialty pharmaceutical company focused on licensing, marketing and distributing established therapeutics in Brazil and Mexico.

V
Vybion

Vybion is a developer and manufacturer of recombinant proteins for therapeutic and diagnostic applications. It uses its technologies along with a highly skilled staff to develop therapeutics, vaccines, diagnostics and bioavailability for pharmaceutical and biotechnology companies.

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.